NOTICE OF CHANGE OF SERVICE

DATE: January 4, 2010
TO: Housestaff and PCN Physicians, Faculty, and Nursing Personnel
FROM: Sridevi Devaraj, PhD., DABCC, FACB
       Director of Toxicology and Special Chemistry
RE: SIROLIMUS TESTING

Effective January 11, 2010 the Sirolimus (Rapamycin) Testing will be performed using the LC/MS/MS methodology. Sirolimus is an immunosuppressant drug used following transplant. The change in methodology is required because the current Microparticle Enzyme Immunoassay (MEIA) test for Sirolimus has been discontinued by the manufacturer. In house validation studies showed an average increase in values of 5%, with individual variation seen. It should be noted that Sirolimus concentrations can vary according to the methodology used, and results from different methodologies cannot be used interchangeably due to differences in cross reactivity with metabolites.

Reference Internal: 7 – 29 ng/mL
The Sirolimus (Rapamycin) reference interval and dosing is very individualized and variable.

Sample Requirement: One 5-mL EDTA tube

Routine Testing: Performed Tuesday and Friday

If you have any questions, please contact Dr. Sridevi Devaraj at 4-6594, or John Tsushima at 4-2741.

APPROVED: Lydia P. Howell, MD
Professor and Acting Chair
Department of Pathology and Laboratory Medicine

cc: Allan Siefkin, MD
    Darrell O’Sullivan
    Richard Perez, MD
    Bettye Andreos
    John Rutledge, MD
    Angelo DeMattos, MD
    Kurt Slapnik, MD
    Jeff Gregg, MD